Table 1. Phenotype of large-scale expanded TIL from melanoma-invaded lymph nodes of 47 patients treated by TIL.
Patients | Relapse-free survivalc | % CD2-positiveb | % CD3-positiveb | % CD3/CD4-positiveb | % CD3/CD8-positiveb | % CD3/CD25-positiveb | |||||
E1a | E2 | E1 | E2 | E1 | E2 | E1 | E2 | E1 | E2 | ||
M88* | + | ND | ND | 100 | 100 | 27 | 39 | 71 | 56 | ND | 19 |
M110 | −(7) | 100 | 99 | 99 | 99 | 78 | 84 | 18 | 18 | 51 | 40 |
M113 | −(6.5) | 100 | 100 | 99 | 100 | 36 | 75 | 63 | 28 | 9 | 42 |
M117 | + | 100 | 100 | 100 | 100 | 30 | 3 | 70 | 97 | 41 | 14 |
M125 | −(3) | 100 | 100 | 99 | 100 | 71 | 65 | 30 | 36 | 56 | 27 |
M131 | −(5) | 100 | 100 | 100 | 100 | 35 | 40 | 62 | 57 | 38 | 60 |
M132 | −(2) | 100 | 100 | 100 | 100 | 39 | 20 | 58 | 80 | 45 | 27 |
M134 | + | 100 | 100 | 100 | 100 | 55 | 62 | 45 | 38 | 25 | 22 |
M140 | + | 100 | 100 | 100 | 100 | 81 | 81 | 19 | 19 | 30 | 22 |
M153 | −(3) | 100 | 100 | 100 | 100 | 34 | 35 | 61 | 56 | 12 | 19 |
M154* | −(156) | 100 | 100 | 100 | 100 | 59 | 63 | 40 | 39 | 12 | 17 |
M158 | −(5) | 100 | 100 | 100 | 100 | 30 | 31 | 70 | 63 | 9 | 16 |
M164 | −(26) | 100 | 100 | 100 | 100 | 60 | 61 | 38 | 39 | 28 | 14 |
M167 | −(4) | 100 | 100 | 100 | 100 | 24 | 18 | 74 | 79 | 15 | 12 |
M170* | + | 100 | 100 | 100 | 100 | 30 | 32 | 67 | 67 | 16 | 36 |
M171 | −(3) | 100 | 100 | 100 | 100 | 48 | 42 | 52 | 58 | 19 | 11 |
M177* | + | 100 | 100 | 100 | 100 | 42 | 63 | 56 | 32 | 34 | 24 |
M182 | + | 100 | 100 | 100 | 100 | 87 | 25 | 13 | 71 | 54 | 31 |
M187 | + | 100 | 100 | 100 | 100 | 16 | 24 | 86 | 76 | 5 | 10 |
M193 | −(4) | 100 | 100 | 100 | 100 | 14 | 27 | 86 | 73 | 7 | 15 |
M196* | −(6) | 100 | 100 | 100 | 100 | 40 | 22 | 58 | 74 | 17 | 8 |
M197* | + | 100 | 100 | 100 | 100 | 48 | 32 | 52 | 68 | 13 | 14 |
M199 | −(2) | 100 | 100 | 100 | 100 | 25 | 14 | 75 | 86 | 33 | 19 |
M200 | −(7) | 100 | 100 | 100 | 100 | 38 | 37 | 42 | 57 | 11 | 16 |
M204 | −(3) | 100 | 100 | 100 | 100 | 92 | 88 | 8 | 17 | 11 | 7 |
M212 | −(8) | 100 | 100 | 99 | 98 | 52 | 33 | 47 | 57 | 13 | 13 |
M218* | + | 99 | 100 | 100 | 100 | 44 | 5 | 55 | 96 | ND | ND |
M234* | −(26) | 100 | 100 | 100 | 100 | 62 | 49 | 42 | 51 | ND | ND |
M241* | −(13) | 100 | 100 | 100 | 100 | 2 | 25 | 99 | 75 | ND | ND |
M245* | −(8) | 100 | 100 | 100 | 100 | 32 | 26 | 68 | 74 | ND | ND |
M252* | −(2) | 100 | ND | 100 | ND | 26 | ND | 71 | ND | ND | ND |
M254* | + | 100 | 100 | 100 | 100 | 13 | 19 | 87 | 78 | 16 | 37 |
M263* | −(14) | 100 | 100 | 100 | 100 | 22 | 30 | 77 | 68 | 11 | 5 |
M275* | −(8.5) | 99.95 | 99.9 | 99.9 | 99.8 | 14.45 | 19.9 | 85.57 | 79.78 | 20.62 | 4.43 |
M278* | + | 99.93 | 99.98 | 99.84 | 99.87 | 6.11 | 4.8 | 93.17 | 93.91 | 2.02 | 2.26 |
M284* | + | 99.98 | 99.95 | 99.97 | 99.99 | 63.94 | 53.89 | 37.7 | 59.25 | 7.75 | 18.12 |
M288* | + | 99.97 | 99.95 | 100 | 99.71 | 34.48 | 59.72 | 65.07 | 57.73 | 8.88 | 8.56 |
M301* | −(6) | 99.93 | 99.99 | 99.74 | 99.92 | 24.43 | 30.64 | 72.44 | 66.83 | 2.06 | 3.22 |
M305* | + | 99.98 | 99.92 | 99.93 | 100 | 19.1 | 20.08 | 80.9 | 79.99 | 6.22 | 2.97 |
M314* | −(3.5) | 99.9 | 99.94 | 97.64 | 98.86 | 62.64 | 61.72 | 32 | 34.36 | 6.92 | 16.74 |
M329* | −(27) | 99.86 | 100 | 98.63 | 99.45 | 34.65 | 39.97 | 62.88 | 57.22 | 16.2 | 13.09 |
M379* | −(4) | 99.9 | 99.9 | 100 | 99.9 | 31.2 | 29.9 | 68.8 | 71 | 18.4 | 6.4 |
M386* | + | 99.8 | 98.9 | 98.5 | 98.8 | 71.4 | 69.4 | 27.7 | 26.3 | 41.6 | 26 |
M415* | + | 99.7 | 100 | 92 | 84.1 | 51.4 | 42.7 | 40.2 | 41.3 | 18.3 | 43.7 |
M417* | + | 99.9 | 99.8 | 97.6 | 95.8 | 19 | 36.1 | 68.6 | 56.1 | 11.8 | 10.3 |
M424* | + | 99.5 | 99.9 | 99.9 | 99.9 | 41.7 | 44 | 57.2 | 50.4 | 6.2 | 6.2 |
M428* | + | 99.6 | 99.4 | 99.9 | 99.7 | 54.3 | 36.9 | 44.4 | 57.2 | 20.2 | 5.2 |
Melanoma patients bearing only one metastatic lymph node (early stage III patients).
E1 and E2 were TIL populations obtained and reinjected to the patient from respectively the first and the second ex-vivo expansions.
Percentages of CD-positive TIL were estimated by membrane labeling. Cells were analyzed on a FACScalibur.
Relapse-free survival of patients (−): patients who relapsed,(months); (+): patients who did not relapse.